2009
DOI: 10.1016/s2173-5115(09)70102-2
|View full text |Cite
|
Sign up to set email alerts
|

Endoluminal high dose rate brachytherapy in the treatment of primary and recurrent bronchogenic tree malignancies

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2010
2010
2014
2014

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(1 citation statement)
references
References 21 publications
0
1
0
Order By: Relevance
“…In addition, from 2010‐2012, Smith et al (5) reported on seven patients with locally advanced low rectal adenocarcinoma (within 12 cm of the anal verge) in a prospective study of neoadjuvant EBT (NCT01226979) at Johns Hopkins Hospital. Finally, Fortunato et al (6) demonstrate the advantages of endoluminal brachytherapy with high‐dose‐rate (HDR) in primary and recurrent tumor of the bronchial tree using seven patients with primary tumors of the colon, trachea, and lung.…”
Section: Introductionmentioning
confidence: 99%
“…In addition, from 2010‐2012, Smith et al (5) reported on seven patients with locally advanced low rectal adenocarcinoma (within 12 cm of the anal verge) in a prospective study of neoadjuvant EBT (NCT01226979) at Johns Hopkins Hospital. Finally, Fortunato et al (6) demonstrate the advantages of endoluminal brachytherapy with high‐dose‐rate (HDR) in primary and recurrent tumor of the bronchial tree using seven patients with primary tumors of the colon, trachea, and lung.…”
Section: Introductionmentioning
confidence: 99%